Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
ORAGENICS INC OGEN

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 16, 2026 8-K 12 signals fired
Core
Clinical Trial Result Lead Asset Progress Combination Therapy Mentioned Indication Expansion
Other
Fda Aligned Interim Data Positive Patient Retention High Enrollment Ahead Of Schedule Forward Looking Statement Definition Expanded Access Program Active Protocol Amended
Biotech v3
Ind Submission Planned
Aug 28, 2026 8-K 5 signals fired
Core
Lead Asset Progress Indication Expansion
Other
Nasdaq Minimum Bid Price Delisting Notice Net Loss Reported
Biotech v3
Ind Submission Planned
Aug 13, 2026 10-Q 17 signals fired · top 15
Other
Net Loss Reported Financing Activities Cash Flow Disclosure Litigation Defense Assertion Cash Flow Statement Investing Activities Patient Retention High Other Income Expense Disclosure Personnel Cost Decrease Disclosure Shareholder Dilution Warning Shares Outstanding Disclosure Auto Insurance Premium Growth Disclosure Nyse Listing Disclosure Gene Therapy Aav
Core
Clinical Trial Result Indication Expansion Patient Enrollment Velocity
Jul 6, 2026 8-K 10 signals fired
Other
Executive Educational Background Disclosure Classified Board Director Election Confidential Information Return Obligation Non Solicitation Covenant Adea Waiver Release President Duties Defined Confidential Information Definition Executive Severance Change Of Control Severance Payment Obligation Stock Option Grant Disclosed
May 19, 2026 8-K 11 signals fired
Other
Ceo Team Pride Statement Expanded Access Program Active Enrollment Ahead Of Schedule Interim Data Positive
Core
Clinical Trial Result Lead Asset Progress Clinical Hold Indication Expansion Secondary Endpoint Mentioned
Biotech v3
Ind Submission Planned
Biotech Risk
Clinical Hold Active
May 8, 2026 10-Q 31 signals fired · top 15
Other
Capital Raising Uncertainty Disclosed Net Loss Reported Financing Activities Cash Flow Disclosure Other Income Expense Disclosure Cash Flow Statement Investing Activities Shareholder Dilution Warning Expanded Access Program Active Interim Data Positive Convertible Debt Conversion Enrollment Ahead Of Schedule Personnel Cost Decrease Disclosure Form S3 Shelf Registration Disclosure
Core
Patient Enrollment Velocity Clinical Trial Result
Biotech Risk
Clinical Hold Active
May 7, 2026 8-K 6 signals fired
Core
Combination Therapy Mentioned Lead Asset Progress Indication Expansion
Other
Fast Track Granted Closing Deliverables Specified Safety Differentiated
Apr 13, 2026 8-K 23 signals fired · top 15
Core
Clinical Trial Result Lead Asset Progress Clinical Hold Indication Expansion Secondary Endpoint Mentioned Combination Therapy Mentioned
Other
Interim Data Positive Fda Aligned Patient Retention High Enrollment Ahead Of Schedule Publication Positive First Patient Treated Fast Track Granted
Biotech v3
Ind Submission Planned
Biotech Risk
Clinical Hold Active